Structure and ligand based drug design strategies in the development of novel 5-LOX inhibitors

Current Medicinal Chemistry

Volumn 19, Issue 22, 2012, Pages 3763-3778

  Aparoy, Polamarasetty ^a   Reddy, Kakularam Kumar ^a   Reddanna, Pallu ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

5 LOX; Arachidonic acid; Asthma; Drug design; Pharmacophore; Pseudoreceptor; QSAR; Scaffold hopping

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; ATRELEUTON; CELECOXIB; CHEBULAGIC ACID; DOCEBENONE; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; PEP 03; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; QUIFLAPON; UNCLASSIFIED DRUG; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASTHMA; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER AIDED DESIGN; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVE SITE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LIGAND BASED DRUG DESIGN; LIVER TOXICITY; MOLECULAR DOCKING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOPHORE; PROTEIN EXPRESSION; PSEUDORECEPTOR MODELING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; SCAFFOLD HOPPING; STRUCTURE BASED DRUG DESIGN; X RAY CRYSTALLOGRAPHY;

ASTHMA; DRUG DESIGN; HUMANS; LIGANDS; LIPOXYGENASE INHIBITORS; LIPOXYGENASES; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865209497     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801661112     Document Type: Review

References (160)

1. Vane, J.R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature-New Biol., 1971, 231(25), 232-235.
2. Agarwal, S.; Reddy, G.V.; Reddanna, P. Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev. Clin. Immunol., 2009, 5(2), 145-165.
3. Reddy, R.N.; Mutyala, R.; Aparoy, P.; Reddanna, P.; Reddy, M.R. Computer aided drug design approaches to develop cyclooxygenase based novel antiinflammatory and anti-cancer drugs. Curr. Pharm. Des., 2007, 13(34), 3505-3517. (Pubitemid 350238940)
4. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56(3), 387-437. (Pubitemid 39096597)
5. Wenzel, S.E. Arachidonic acid metabolites: Mediators of inflammation in asthma. Pharmacotherapy, 1997, 17(1), S3-S12.
6. Pontiki, E.; Hadjipavlou-Litina, D. Lipoxygenase inhibitors: A comparative QSAR study review and evaluation of new QSARs. Med. Res. Rev., 2008, 28(1), 39-117. (Pubitemid 350274961)
7. Funk, C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science, 2001, 294(5548), 1871-1875. (Pubitemid 33101574)
8. Boyington, J.C.; Gaffney, B.J.; Amzel, L.M. Crystallization and Preliminary-X-Ray Analysis of Soybean Lipoxygenase-1, a Nonheme Iron-Containing Dioxygenase. J. Biol. Chem., 1990, 265(22), 12771-12773.
9. Minor, W.; Steczko, J.; Stec, B.; Otwinowski, Z.; Bolin, J.T.; Walter, R.; Axelrod, B. Crystal structure of soybean lipoxygenase L-l at 1.4 angstrom resolution. Biochemistry, 1996, 35(33), 10687-10701. (Pubitemid 26279648)
10. Brash, A.R. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem., 1999, 274(34), 23679-23682.
11. Meruvu, S.; Walther, M.; Ivanov, I.; Hammarstrom, S.; Furstenberger, G.; Krieg, P.; Reddanna, P.; Kuhn, H. Sequence determinants for the reaction specificity of murine (12R)-lipoxygenase: targeted substrate modification and site-directed mutagenesis. J. Biol. Chem., 2005, 280(44), 36633-36641. (Pubitemid 41587740)
12. Aparoy, P.; Leela, T.; Reddy, R.N.; Reddanna, P. Computational analysis of R and S isoforms of 12-Lipoxygenases: Homology modeling and docking studies. J. Mol. Graph. Model., 2009, 27(6), 744-750.
13. Rapoport, S.M.; Schewe, T.; Wiesner, R.; Halangk, W.; Ludwig, P.; Janicke-Hohne, M.; Tannert, C.; Hiebsch, C.; Klatt, D. The lipoxygenase of reticulocytes. Purification, characterization and biological dynamics of the lipoxygenase; its identity with the respiratory inhibitors of the reticulocyte. Eur. J. Biochem., 1979, 96(3), 545-561.
14. Funk, C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov., 2005, 4(8), 664-672. (Pubitemid 41149760)
15. Ivanov, I.; Heydeck, D.; Hofheinz, K.; Roffeis, J.; O'Donnell, V.B.; Kuhn, H.; Walther, M. Molecular enzymology of lipoxygenases. Arch. Biochem. Biophys., 2010, 503(2), 161-174.
16. Pergola, C.; Jazzar, B.; Rossi, A.; Buehring, U.; Luderer, S.; Dehm, F.; Northoff, H.; Sautebin, L.; Werz, O. Cinnamyl-3, 4-Dihydroxy-alpha- Cyanocinnamate Is a Potent Inhibitor of 5-Lipoxygenase. J. Pharmacol. Exp. Ther., 2011, 338(1), 205-213.
17. Mancini, J.A.; Abramovitz, M.; Cox, M.E.; Wong, E.; Charleson, S.; Perrier, H.; Wang, Z.Y.; Prasit, P.; Vickers, P.J. 5-Lipoxygenase-Activating Protein Is an Arachidonate Binding-Protein. Febs Lett., 1993, 318(3), 277-281.
18. Peters-Golden, M.; Brock, T.G. 5-lipoxygenase and FLAP. Prostag. Leukotr. Ess., 2003, 69(2-3), 99-109. (Pubitemid 36976166)
19. Muller, K. 5-Lipoxygenase and 12-lipoxygenase: attractive targets for the development of novel antipsoriatic drugs. Arch. Pharm. (Weinheim), 1994, 327(1), 3-19. (Pubitemid 24035620)
20. Mandal, A.K.; Skoch, J.; Bacskai, B.J.; Hyman, B.T.; Christmas, P.; Miller, D.; Yamin, T.T.; Xu, S.; Wisniewski, D.; Evans, J.F.; Soberman, R.J. The membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci., 2004, 101(17), 6587-6592. (Pubitemid 38586018)
21. Ma, X.; Zhou, L.; Zuo, Z.L.; Liu, J.; Yang, M.; Wang, R.W. Molecular docking and 3-D QSAR studies of substituted 2, 2-bisaryl-bicycloheptanes as human 5-Lipoxygenase-Activating Protein (FLAP) inhibitors. Qsar. Comb. Sci., 2008, 27(9), 1083-1091.
22. Chang, M.; Rao, M.K.; Reddanna, P.; Li, C.H.; Tu, C.P.; Corey, E.J.; Reddy. C.C. Specificity of the glutathione S-transferases in the conversion of leukotriene A4 to leukotriene C4. Arch. Biochem. Biophys., 1987, 259(2), 536-547. (Pubitemid 18022770)
23. Werz, O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug. Targets Inflamm. Allergy, 2002, 1(1), 23-44.
24. Reddanna, P.; Prabhu, K.S.; Whelan, J.; Reddy, C.C. Carboxypeptidase Acatalyzed direct conversion of leukotriene C4 to leukotriene F4. Arch. Biochem. Biophys., 2003, 413(2), 158-163. (Pubitemid 36506803)
25. Radmark, O.; Werz, O.; Steinhilber, D.; Samuelsson, B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci., 2007, 32(7), 332-341. (Pubitemid 47021417)
26. Davidson, E.M.; Rae, S.A.; Smith, M.J. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis. Ann. Rheum. Dis., 1983, 42(6), 677-679. (Pubitemid 14205436)
27. Nie, D.T.; Che, M.; Grignon, D.; Tang, K.Q.; Honn, K.V. Role of eicosanoids in prostate cancer progression. Cancer Metast. Rev., 2001, 20(3-4), 195-206. (Pubitemid 34595268)
28. Anderson, K.M.; Seed, T.; Vos, M.; Mulshine, J.; Meng, J.; Alrefai, W.; Ou, D.; Harris, J. E. 5-lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate, 1998, 37(3), 161-173. (Pubitemid 28487899)
29. Avis, I.M.; Jett, M.; Boyle, T.; Vos, M.D.; Moody, T.; Treston, A.M.; Martinez, A.; Mulshine, J.L. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest., 1996, 97(3), 806-813. (Pubitemid 26057100)
30. Schneider, C.; Pozzi, A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev., 2011, 30(3-4), 277-294.
31. Chen, Y.; Hu, Y.; Zhang, H.; Peng, C.; Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet., 2009, 41(7), 783-92.
32. Carter, G.W.; Young, P.R.; Albert, D.H.; Bouska, J.; Dyer, R.; Bell, R.L.; Summers, J.B.; Brooks, D.W. 5-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther., 1991, 256 (3), 929-937.
33. Catalano, A.; Procopio, A. New aspects on the role of lipoxygenases in cancer progression. Hist. Histopath., 2005, 20(3), 969-975. (Pubitemid 40932614)
34. Hong, S.H.; Avis, I.; Vos, M.D.; Martinez, A.; Treston, A.M.; Mulshine, J.L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res., 1999, 59(9), 2223-2228. (Pubitemid 29217689)
35. Hennig, R.; Ding, X.Z.; Tong, W.G.; Schneider, M.B.; Standop. J.; Friess, H.; Büchler, M.W.; Pour, P.M.; Adrian, T.E. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol., 2002, 161(2), 421-428. (Pubitemid 36142151)
36. Gupta, S.; Srivastava, M.; Ahmad, N.; Sakamoto, K.; Bostwick, D.G.; Mukhtar, H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 2001, 91(4), 737-743. (Pubitemid 32173298)
37. Sarveswaran, S.; Thamilselvan, V.; Brodie, C.; Ghosh, J. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim. Biophys. Acta., 2011, 1813(12), 2108-2117.
38. Sarveswaran, S.; Myers, C.E.; Ghosh, J. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett., 2010, 29(2), 167-176.
39. Ding, X.Z.; Kuszynski, C. A.; El-Metwally, T.H.; Adrian, T.E. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem. Biophys. Res. Commun., 1999, 266(2), 392-399. (Pubitemid 30028679)
40. Ding, X.; Zhu, C.; Qiang, H.; Zhou, X.; Zhou, G. Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors. Biomed. Pharmacother., 2011, 65(7), 486-490.
41. Hoque, A.; Lippman, S.M.; Wu, T.T.; Xu, Y.; Liang, Z.D.; Swisher, S.; Zhang, H.; Cao, L.; Ajani, J.A.; Xu, X.C. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis, 2005, 26(4), 785-791. (Pubitemid 41214341)
42. Zou, L.Y.; Li, J.Y.; Chen, F.L; Chen, Z.X; Wang X.W. Tumor 5-Lipoxygenase Expression Correlates with Gastric Cancer Metastasis and Its Selective Inhibitor Induces Cancer Cell Apoptosis. J. of Cancer Molecules, 2006, 2(6), 227-233.
43. Melstrom, L.G.; Bentrem, D.J.; Salabat, M.R.; Kennedy, T.J.; Ding, X.Z.; Strouch, M.; Rao, S.M.; Witt, R.C.; Ternent, C.A.; Talamonti, M.S.; Bell, R.H.; Adrian, T.A. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin. Cancer Res., 2008, 14(20), 6525-6530.
44. Reddy, N.P.; Reddy, C.M.; Aparoy, P.; Achari, C.; Ramu Sridhar, P.; Reddanna, P. Structure Based Drug Design, Synthesis and Evaluation of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives as 5-Lipoxygenase inhibitors, Eur. J. .Med. Chem., 2012, 47(1), 351-359.
45. Reddy, N.P.; Aparoy, P.; Reddy, T.C.; Achari, C.; Sridhar, P.R.; Reddanna, P. Design, synthesis, and biological evaluation of prenylated chalcones as 5-LOX inhibitors. Bioorg. Med. Chem., 2010, 18(16), 5807-5815.
46. Rabasseda, X.; Mealy, N.; Castañer, J. ML3000. Drugs of the future, 1995, 20, 1007-9.
47. Kuehl, F.A.; Daugherty, H.W.; Ham, E.A. Interaction between prostaglandins and leukotrienes. Biochem. Pharmacol., 1984, 33, 1-5.
48. Dworski, R.; Sheller, J.R.; Wickersham, N.E.; Oates, J.A.; Brigham, K.L.; Roberts, L.J.; Fitzgerald, G.A. Allergen-stimulated release of mediators into sheep bronchoalveolar lavage fluid. Effect of cyclooxygenase inhibition. Am. Rev. Respir. Dis., 1989, 139, 46-51. (Pubitemid 19030421)
49. Fiorucci, S.; Meli, R.; Bucci, M.; Cirino, G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol., 2001, 62(11), 1433-1438. (Pubitemid 33145286)
50. Cianchi, F.; Cortesini, C.; Magnelli, L.; Fanti, E.; Papucci, L.; Schiavone, N.; Messerini, L.; Vannacci, A.; Capaccioli, S.; Perna, F.; Lulli, M.; Fabbroni, V.; Perigli, G.; Bechi, P.; Masini, E. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther., 2006, 5(11), 2716-2726. (Pubitemid 44848998)
51. Goulet, J.L.; Snouwaert, J.N.; Latour, A.M.; Coffman, T.M.; Koller, B.H. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci., 1994, 91(26), 12852-12856.
52. Peters-Golden, M.; Bailie, M.; Marshall, T.; Wilke, C.; Phan, S.H.; Toews, G.B.; Moore, B.B. Protection from pulmonary fibrosis in leukotrienedeficient mice. Am. J. Respir. Crit. Care. Med., 2002, 165(2), 229-235. (Pubitemid 34084463)
53. Ye, Y.N.; Wu, W.K.; Shin, V.Y.; Bruce, I.C.; Wong, B.C.; Cho, C.H. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis, 2005, 26(4), 827-834. (Pubitemid 41214346)
54. Li, N.; Sood, S.; Wang, S.; Fang, M.; Wang, P.; Sun, Z.; Yang, C.S.; Chen, X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res., 2005, 11(5), 2089-2096. (Pubitemid 40471876)
55. Chen, X.; Wang, S.; Wu, N.; Sood, S.; Wang, P.; Jin, Z.; Beer, D.G.; Giordano, T.J.; Lin, Y.; Shih, W.C.; Lubet, R.A.; Yang, C.S. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res., 2004, 10(19), 6703-6709. (Pubitemid 39346568)
56. Narayanan, N.K.; Nargi, D.; Attur, M.; Abramson, S.B.; Narayanan, B.A. Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res., 2007, 27(4B), 2393-2402. (Pubitemid 47228080)
57. Tavolari, S.; Bonafè, M.; Marini, M.; Ferreri, C.; Bartolini, G.; Brighenti, E.; Manara, S.; Tomasi, V.; Laufer, S.; Guarnieri, T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis, 2008, 29(2), 371-380. (Pubitemid 351359677)
58. Reddy, D.B.; Reddy, T.C.; Jyotsna, G.; Sharan, S.; Priya, N.; Lakshmipathi, V.; Reddanna, P. Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J. Ethnopharmacol., 2009, 124(3), 506-512.
59. Reddy, D.B.; Reddanna, P. Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. Biochem. Biophys. Res. Commun., 2009, 381(1), 112-117.
60. Young, R. Inhibition of 5-lipoxygenase: A therapeutic potential yet to be fully realized? Eur. J. Med. Chem. 1999, 34, 671-685. (Pubitemid 29491553)
61. Liu, W.; Zhou, J.; Liu, Y.; Liu, H.; Bensdorf, K.; Guo, C.; Gust, R. Licofelone-nitric oxide donors as anticancer agents. Arch. Pharm. (Weinheim)., 2011, 344(8), 487-493.
62. Berger, W.; De Chandt, M. T.; Cairns, C. B. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract., 2007, 61, 663-676. (Pubitemid 46449830)
63. Prescribing Information for ZYFLO CR; Cornerstone Therapeutics, Inc: Lexington, MA, May 2007.
64. Steele, V.E.; Holmes, C.A.; Hawk, E.T.; Kopelovich, L.; Lubet, R.A.; Crowell, J.A.; Sigman, C.C.; Kelloff, G.J. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 1999, 8(5), 467-483. (Pubitemid 29230553)
65. Williams, F.M.; Spector, T.D. A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis. Nat. Clin. Pract. Rheumatol., 2009, 5(3), 132-133.
66. Tardif, J.C; L'allier, P.L.; Ibrahim, R.; Grégoire, J.C.; Nozza, A.; Cossette, M.; Kouz, S.; Lavoie, M.A.; Paquin, J.; Brotz, T.M.; Taub, R.; Pressacco, J. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging, 2010, 3(3), 298-307.
67. Kapetanovic, I.M. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chem-Biol. Interact., 2008, 171(2), 165-176. (Pubitemid 351146652)
68. Shaikh, S.A.; Jain, T.; Sandhu, G.; Latha, N.; Jayaram, B. From drug target to leads-sketching a physicochemical pathway for lead molecule design in silico. Curr. Pharm. Design, 2007, 13(34), 3454-3470. (Pubitemid 350238936)
69. Kroemer, R.T. Structure-based drug design: Docking and scoring. Curr. Protein Pept. Sc., 2007, 8(4), 312-328. (Pubitemid 47317039)
70. Cavasotto, C.N.; Phatak, S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today, 2009, 14(13-14), 676-683.
71. Krieger, E.; Nabuurs, S.B.; Vriend, G. Homology modeling. Methods Biochem. Anal., 2003, 44, 509-523.
72. Murcko, M.A. In: Reviews in Computational Chemistry; Lipkowitz, K.B.; Boyd, D.B., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2007; Vol. 11, pp. 1-67.
73. Gane, P.J.; Dean, P.M. Recent advances in structure-based rational drug design. Curr. Opin. Struc. Biol., 2000, 10(4), 401-404. (Pubitemid 30496791)
74. Ghosh, S.; Nie, A.H.; An, J.; Huang, Z.W. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol., 2006, 10(3), 194-202. (Pubitemid 43815778)
75. Lyne, P.D. Structure-based virtual screening: an overview. Drug Discov. Today, 2002, 7(20), 1047-1055.
76. Shoichet, B.K. Virtual screening of chemical libraries. Nature, 2004, 432(7019), 862-865. (Pubitemid 40037142)
77. Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J.L. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem., 2010, 18(2), 822-829.
78. Pierri, C.L.; Parisi, G.; Porcelli, V. Computational approaches for protein function prediction: a combined strategy from multiple sequence alignment to molecular docking-based virtual screening. Biochim. Biophys. Acta., 2010, 1804(9), 1695-1712.
79. Finn, J. Application of SBDD to the Discovery of New Antibacterial Drugs. Methods Mol. Biol., 2012, 841, 291-319.
80. Wang, D.; Wang, F.; Tan, Y.; Dong, L.; Chen, L.; Zhu, W.; Wang, H. Discovery of potent small molecule inhibitors of DYRK1A by structurebased virtual screening and bioassay. Bioorg. Med. Chem. Lett., 2012, 22(1), 168-171.
81. Taylor, R.D.; Jewsbury, P.J.; Essex, J.W., A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des., 2002, 16(3), 151-166.
82. Waszkowycz, B. Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discov. Devel., 2002, 5(3), 407-413. (Pubitemid 36285646)
83. Jenwitheesuk, E.; Samudrala, R. Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. AIDS, 2005, 19(5), 529-531. (Pubitemid 40515858)
84. Acharya, C.; Coop, A.; Polli, J.E.; Mackerell, A.D. Jr. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr. Comput. Aided Drug Des., 2011, 7(1), 10-22.
85. Gilbert, N.C.; Bartlett, S.G.; Waight, M.T.; Neau, D.B.; Boeglin, W.E.; Brash, A.R.; Newcomer, M.E. The structure of human 5-lipoxygenase. Science, 2011, 331(6014), 217-219.
86. Du, L.; Zhang, Z.; Luo, X.; Chen, K.; Shen, X.; Jiang, H. Binding investigation of human 5-lipoxygenase with its inhibitors by SPR technology correlating with molecular docking simulation. J. Biochem., 2006, 139(4), 715-723. (Pubitemid 43973918)
87. Charlier, C.; Henichart, J.P.; Durant, F.; Wouters, J. Structural insights into human 5-lipoxygenase inhibition: Combined ligand-based and target-based approach. J. Med. Chem., 2006, 49(1), 186-195. (Pubitemid 43077332)
88. Whelan, J.; Reddanna, P.; Nikolaev, V.; Hildebrandt, G.; Reddy, C.C. In: Biological oxidation systems; Reddy, C.C.; Hamilton, G.A.; Madyastha, K.M., Eds.; Academic Press: San Diego, CA, 1988; Vol. 2, pp. 765-778.
89. Skrzypczak-Jankun, E.; Borbulevych, O.Y.; Jankun, J. Soybean lipoxygenase-3 in complex with 4-nitrocatechol. Acta. Crystallogr. D Biol. Crystallogr., 2004, 60(Pt3), 613-615. (Pubitemid 41087613)
90. Aparoy, P.; Reddy, R.N.; Guruprasad, L.; Reddy, M.R.; Reddanna, P. Homology modeling of 5-lipoxygenase and hints for better inhibitor design. J. Comput. Aided Mol. Des., 2008, 22(9), 611-619.
91. Aparoy, P. Rational approaches in the development of novel 5-Lipoxygenase inhibitors: Structure and Ligand Based Drug Design strategies. PhD Thesis, University of Hyderabad: Hyderabad, February 2010.
92. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267(3), 727-748. (Pubitemid 27170693)
93. Singh, U.C.; Weiner, P.K.; Caldwell, J.K. and Kollman P.A. AMBER version 3.0, University of California, San Francisco, CA, 1986.
94. LUDI user guide, Accelrys, Inc., San Diego, USA; 1999
95. Barhate, N.B.; Madhava R.C.; Srinivasa, R.P.; Wakharkar, R.D.; Reddanna, P. Synthesis and biochemical evaluation of benzyl propargyl ethers as inhibitors of 5-lipoxygenase. Indian J. Biochem. Biophys., 2002, 39, 264-273. (Pubitemid 36928227)
96. Reddanna, P.; Whelan, J.; Maddipati, K.R.; Reddy, C.C. Purification of arachidonate 5-lipoxygenase from potato tubers. Methods Enzymol., 1990, 187, 268-277. (Pubitemid 20309290)
97. Tan, C.M.; Chen, G.S.; Chen, C.S.; Chang, P.T.; Chern, J.W. Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1, 1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors. Bioorg. Med. Chem., 2011, 19(21), 6316-6328.
98. Yu, G.; Chowdhury, M.A.; Abdellatif, K.R.A.; Dong, Y.; Rao, P.N.P.; Das, D.; Velazquez, C.A.; Suresh, M.R.; Knaus, E.E. Phenylacetic acid regioisomers possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one pharmacophore: Evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem. Lett., 2010, 20(3), 896-902.
99. Zheng, M.F.; Zheng, M.Y.; Ye, D.J.; Deng, Y.M.; Qiu, S.F.; Luo, X.M.; Chen, K.X.; Liu, H.; Jiang, H.L. Indole derivatives as potent inhibitors of 5-lipoxygenase: Design, synthesis, biological evaluation, and molecular modeling. Bioorg. Med. Chem. Lett., 2007, 17(9), 2414-2420. (Pubitemid 46522523)
100. Moreau, A.; Chen, Q.H.; Rao, P.N.P.; Knaus, E.E. Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg. Med. Chem., 2006, 14(23), 7716-7727. (Pubitemid 44584724)
101. Winkler, D.A. The role of quantitative structure-activity relationships (QSAR) in biomolecular discovery. Brief Bioinform., 2002, 3(1), 73-86.
102. Eleni, P.; Dimitra, H.L. Review in quantitative structure activity relationships on lipoxygenase inhibitors. Mini Rev. Med. Chem., 2003, 3(5), 487-499.
103. Merz, Jr.; Kenneth, M.; Ringe, D.; Reynolds, C.H. Drug Design. Cambridge University Press, 2010.
104. Dudek, A.Z.; Arodz, T.; Galvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb. Chem. High Throughput Screen., 2006, 9(3), 213-228.
105. Aparoy, P.; Suresh, G.K.; Reddy, K.K.; Reddanna, P. CoMFA and CoMSIA studies on 5-hydroxyindole-3-carboxylate derivatives as 5-lipoxygenase inhibitors: Generation of homology model and docking studies. Bioorg. Med. Chem. Lett., 2011, 21(1), 456-462.
106. Karg, E.M.; Luderer, S.; Pergola, C.; Bühring, U.; Rossi, A.; Northoff, H.; Sautebin, L.; Troschütz, R.; Werz, O. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J. Med. Chem., 2009, 52(11), 3474-3483.
107. SYBYL Molecular Modeling Software, Version 8.0, Tripos Inc., St. Louis, MO.
108. Aparoy, P.; Reddy, K.K.; Kalangi, S.K.; Reddy, T.C.; Reddanna, P. Pharmacophore modeling and virtual screening for designing potential 5-Lipoxygenase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1013-1018.
109. Zheng, J.; Xiao, G.; Guo, J.; Zheng, Y.; Gao, H.; Zhao, S.; Zhang, K.; Sun, P. Exploring QSARs for 5-lipoxygenase (5-LO) inhibitory activity of 2-substituted 5-hydroxyindole-3-carboxylates by CoMFA and CoMSIA. Chem. Biol. Drug Des., 2011, 78(2), 314-321.
110. Choudhary, A.N.; Kumar, A.; Juyal, V. Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors. Mini-Rev. Med. Chem., 2010, 10(8), 705-714.
111. Yadav, R.; Srivastava, S.D.; Srivastava, S.K. Synthesis, antimicrobial and anti-inflammatory activities of 4-oxothiazolidines and their 5-arylidenes. Indian J. Chem. Sect. B, 2005, 44B, 1262-1266. (Pubitemid 41159709)
112. Agrawal, V.K.; Bano, S.; Khadikar, P.V. QSAR study on 5-lipoxygenase inhibitors using distance-based topological indices. Bioorg. Med. Chem., 2003, 11(24), 5519-5527. (Pubitemid 37464679)
113. Kim, K.H.; Martin, Y.C.; Brooks, C.D.W. Quantitative structure-activity relationships of 5-lipoxygenase inhibitors. Inhibitory potency of triazinone analogues in a broken cell. Quant. Struct. Act. Rel., 1996, 15(6), 491-497. (Pubitemid 27023203)
114. Revathi, S.; Gupta, A.K.; Soni, L.K.; Kavitha, S.; Wagh, R.; Kaskhedikar, S.G. Rationalization of physicochemical characters of 1, 5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: A QSAR approach. J. Pharmaceut. Biomed., 2006, 42(2), 283-289. (Pubitemid 44279336)
115. Pommery, N.; Taverne, T.; Telliez, A.; Goossens, L.; Charlier, C.; Pommery, J.; Goossens, J.F.; Houssin, R.; Durant, F.; Henichart, J.P. New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J. Med. Chem., 2004, 4 (25), 6195-6206. (Pubitemid 39587244)
116. McMillan, R.M.; Spruce, K.E.; Crawley, G.C.; Walker, E.R.; Foster, S.J. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br. J. Pharmacol., 1992, 107(4), 1042-1047.
117. Sivakumar, P.M.; Babu, S.K.G.; Sharma, V.; Doble, M. QSAR and Docking Studies on Propenone Derivatives as Dual COX and 5-LOX Inhibitors. Lett. Org. Chem., 2008, 5(7), 544-554.
118. Babu, M.A.; Shakya, N.; Prathipati, P.; Kaskhedikar, S.G.; Saxena, A.K. Development of 3D-QSAR models for 5-lipoxygenase antagonists: Chalcones. Bioorg. Med. Chem., 2002, 10(12), 4035-4041. (Pubitemid 36164703)
119. Sogawa, S.; Nihro, Y.; Ueda, H.; Izumi, A.; Miki, T.; Matsumoto, H.; Satoh, T. 3, 4-Dihydroxychalcones as Potent 5-Lipoxygenase and Cyclooxygenase Inhibitors. J. Med. Chem., 1993, 36(24), 3904-3909. (Pubitemid 24006720)
120. Summers, J.B.; Kim, K.H.; Mazdiyasni, H.; Holms, J.H.; Ratajczyk, J.D.; Stewart, A.O.; Dyer, R.D.; Carter, G.W. Hydroxamic Acid Inhibitors of 5-Lipoxygenase -Quantitative Structure-Activity-Relationships. J. Med. Chem., 1990, 33(3), 992-998. (Pubitemid 20085904)
121. Ehrlich, P. Present status of chemotherapy. Chem. Ber., 1909, 42, 17-47.
122. Gund, P. Three-dimensional pharmacophoric pattern searching. Prog. Mol. Subcell. Biol., 1977, 11, 117-143.
123. Güner, O.; Clement, O.; Kurogi, Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr. Med. Chem., 2004, 11(22), 2991-3005. (Pubitemid 39369268)
124. Sun, H., Pharmacophore-based virtual screening. Curr. Med. Chem., 2008, 15(10), 1018-1024. (Pubitemid 351736404)
125. Kim, K.H.; Kim, N.D.; Seong, B.L. Pharmacophore-based virtual screening: a review of recent applications. Expert Opin. Drug Discov., 2010, 5(3), 205-222.
126. Melagraki, G.; Afantitis, A. Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors. Curr. Med. Chem., 2011, 18(17), 2612-2619.
127. Caporuscio, F.; Tafi, A. Pharmacophore Modelling: A Forty Year Old Approach and its Modern Synergies. Curr. Med. Chem., 2011, 18(17), 2543-2553.
128. CATALYST, Version 4.7 Software; Copyright Accelrys Inc.: 2002
129. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45(1), 160-169. (Pubitemid 40736968)
130. Martin, Y.C. In: Pharmacophore Perception, Development and Use in Drug Design; Güner, O.F., Ed., International University Line. La Jolla, CA, 2000; pp. 49-68.
131. Jones, G.; Willet, P. In: Pharmacophore Perception, Development and Use in Drug Design; Güner, O.F., Ed., International University Line, La Jolla, CA, 2000; pp. 85-106.
132. Dixon, S. L.; Smondyrev, A. M.; Rao, S. N., PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching. Chem. Biol. Drug Des., 2006, 67, 370-372
133. Molecular Operating Environment, v.2010, The Chemical Computing Group, Montreal, QC, Canada
134. Mcmillan, R.M.; Walker, E.R.H. Designing Therapeutically Effective 5-Lipoxygenase Inhibitors. Trends Pharmacol. Sci., 1992, 13(8), 323-330.
135. Hutchinson, J.H.; Riendeau, D.; Brideau, C.; Chan, C.; Delorme, D.; Denis, D.; Falgueyret, J.P.; Fortin, R.; Guay, J.; Hamel, P.; Jones, T.R.; Macdonald, D.; Mcfarlane, C.S.; Piechuta, H.; Scheigetz, J.; Tagari, P.; Therien, M.; Girard, Y. Substituted Thiopyrano[2, 3, 4-C, D]Indoles as Potent, Selective, and Orally-Active Inhibitors of 5-Lipoxygenase -Synthesis and Biological Evaluation of L-691, 816. J. Med. Chem., 1993, 36(19), 2771-2787. (Pubitemid 23312674)
136. Hamel, P.; Riendeau, D.; Brideau, C.; Chan, C.C.; Desmarais, S.; Delorme, D.; Dube, D.; Ducharme, Y.; Ethier, D.; Grimm, E.; Falgueyret, J.P.; Guay, J.; Jones, T.R.; Kwong, E.; McAuliffe, M.; McFarlane, C.S.; Piechuta, H.; Roumi, M.; Tagari, P.; Young, R.N.; Girard, Y. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors: Synthesis, biological profile, and pharmacokinetics of L-739, 010. J. Med. Chem., 1997, 40(18), 2866-2875. (Pubitemid 27382537)
137. Mano, T.; Okumura, Y.; Sakakibara, M.; Okumura, T.; Tamura, T.; Miyamoto, K.; Stevens, R.W. 4-[5-fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxylphenyl] -3, 4, 5, 6-tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics. J. Med. Chem., 2004, 47(3), 720-725. (Pubitemid 38129729)
138. Gillmor, S.A.; Villasenor, A.; Fletterick, R.; Sigal, E.; Browner, M.F. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol., 1997, 4(12), 1003-1009. (Pubitemid 27525804)
139. Schwarz, K.; Walther, M.; Anton, M.; Gerth, C.; Feussner, I.; Kuhn, H. Structural basis for lipoxygenase specificity -Conversion of the human leukocyte 5-lipoxygenase to a 15-lipoxygenating enzyme species by sitedirected mutagenesis. J. Bio. Chem., 2001, 276(1), 773-779. (Pubitemid 32050377)
140. Kim, H.J.; Doddareddy M.R.; Choo, H.; Cho, Y.S.; No, K.T.; Park, W.K.; Pae, A.N. New serotonin 5-HT(6) ligands from common feature pharmacophore hypotheses. J. Chem. Inf. Model, 2008, 48(1), 197-206. (Pubitemid 351271065)
141. Fischer, R. In: The Design of Experiments; Eighth Edition. Hafner Publishing Co.: New York, 1966
142. Accelrys Discovery Studio 1.7; Accelrys: San Diego, CA, 2006. http://www.accelrys.com.
143. Sukesh, K.; Vadivelan, S.; Jagarlapudi, S.A. Discovery of Novel 5-LOX Inhibitors: Pharmacophore Design, Homology and Docking Studies. Int. J. Biosci. Biochem. Bioinfo., 2011, 1(1), 10-15.
144. Tsunoyama, K.; Amini, A.; Sternberg, M.J.E.; Muggleton, S.H. Scaffold hopping in drug discovery using inductive logic programming. J. Chem. Inf. Model., 2008, 48(5), 949-957.
145. Bergmann, R.; Linusson, A.; Zamora, I. SHOP: Scaffold HOPping by GRIDbased similarity searches. J. Med. Chem., 2007, 50(11), 2708-2717. (Pubitemid 46896079)
146. Zhao, H.Y. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov.Today, 2007, 12(3-4), 149-155.
147. Renner, S.; Schneider, G. Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem., 2006, 1(2), 181-185. (Pubitemid 43700297)
148. Hofmann, B.; Franke, L.; Proschak, E.; Tanrikulu, Y.; Schneider, P.; Steinhilber, D.; Schneider, G. Scaffold-Hopping Cascade Yields Potent Inhibitors of 5-Lipoxygenase. ChemMedChem, 2008, 3(10), 1535-1538.
149. Proschak, E.; Tanrikulu, Y.; Schneider, G. In: Chemoinformatics: An Approach to Virtual Screening; Varnek, A.; Tropsha, A., Eds.; Royal Society of Chemistry: Cambridge, 2008; pp. 217-239.
150. Hofmann, B.; Barzen, S.; Rodl, C.B.; Kiehl, A.; Borig, J.; Zivkovic, A.; Stark, H.; Schneider, G.; Steinhilber, D. A Class of 5-Benzylidene-2- phenylthiazolinones with High Potency as Direct 5-Lipoxygenase Inhibitors. J. Med. Chem., 2011, 54(6), 1943-1947.
151. Franke, L.; Schwarz, O.; Muller-Kuhrt, L.; Hoernig, C.; Fischer, L.; George, S.; Tanrikulu, Y.; Schneider, P.; Werz, O.; Steinhilber, D.; Schneider, G. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J. Med. Chem., 2007, 50(11), 2640-2646. (Pubitemid 46896071)
152. Schneider, P.; Schneider, G. Collection of bioactive reference compounds for focused library design. Qsar. Comb. Sci., 2003, 22(7), 713-718. (Pubitemid 37391067)
153. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G., "Scaffold- Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem. Int. Ed. Engl., 1999, 38(19), 2894-2896. (Pubitemid 29479958)
154. Fechner, U.; Franke, L.; Renner, S.; Schneider, P.; Schneider, G. Comparison of correlation vector methods for ligand-based similarity searching. J. Comput. Aided Mol. Des., 2003, 17(10), 687-98. (Pubitemid 38344471)
155. Schneider, G.; Schneider, P. In: Chemogenomics in Drug DiscoVery; Kubinyi, H., Müller, G., Eds.; Wiley-VCH: Weinheim, Germa, 2004; pp. 341-376.
156. Vedani, A. Pseudoreceptor modeling -a tool in the pharmacological screening process. ALTEX, 1994, 11(1), 11-21.
157. Tanrikulu, Y.; Schneider, G. Pseudoreceptor models in drug design: bridging ligand-and receptor-based virtual screening. Nat. Rev. Drug Discov., 2008, 7(8), 667-677.
158. Rodl, C.B.; Tanrikulu, Y.; Wisniewska, J.M.; Proschak, E.; Schneider, G.; Steinhilber, D.; Hofmann, B. Potent Inhibitors of 5-Lipoxygenase Identified using Pseudoreceptors. ChemMedChem., 2011, 6(6), 1001-1005.
159. Klebe, G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today, 2006, 11(13-14), 580-594.
160. Waszkowycz, B. Towards improving compound selection in structure-based virtual screening. Drug Discov. Today, 2008, 13(5-6), 219-226.